PDCD1 and melanoma: Clinical studies focusing on melanoma, RCC, squamous cell carcinoma, and NSCLC have shown remarkable increases in patient survival with both CTLA-4 and PD-1 checkpoint inhibitors compared to conventional chemotherapy (89).